Kimberly-Clark prepares concessions to unblock the US$40 billion acquisition of Kenvue
Article excerpt
Highlighted: the sentence this signal was extracted from
Kimberly-Clark is moving forward with a strategy to try to unblock the acquisition of Kenvue in Europe, an operation valued at around US$40 billion, while concerns are growing among community authorities about the impact the transaction would have on competition. According to Reuters, the manufacturer of products such as Kleenex, Huggies, and Kotex would be preparing a series of concessions to respond to the objections that the European Commission will raise. The regulatory body plans to formally communicate its concerns to Kimberly-Clark this week, according to sources close to the process.The operation had already attracted special attention since its announcement due to the size of the companies involved and the number of brands that would fall under the same group. Kenvue owns renowned lines of consumer and personal care products, including Tylenol, Neutrogena, Listerine, Aveeno, and Band-Aid. The concessions being prepared by Kimberly-Clark could thus become a central piece of the negotiation with regulators.This type of commitment may include the sale of certain assets or brands, the transfer of commercial rights, or other measures aimed at preserving competition in markets considered sensitive. For now, it has not been publicly disclosed what assets Kimberly-Clark would be willing to modify or divest. Nor is it defined whether the proposals will be sufficient to...
Keep reading with a free account
The rest of this article, and every signal for Kimberly-Clark, is in your free account.
